H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio (CLYM) to $15 from $11 and keeps a Buy rating on the shares following the Q4 report. The company’s clinical-stage pipeline candidates are “advancing rapidly,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: